{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:25:49Z","timestamp":1779909949986,"version":"3.53.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cmi.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:01:37Z","timestamp":1686225697000},"page":"1196.e1-1196.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Plasma and intraperitoneal pharmacokinetics of ceftazidime\/avibactam in peritoneal dialysis patients"],"prefix":"10.1016","volume":"29","author":[{"given":"Valentin","family":"al Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Matzneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Duc","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisse","family":"van Os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"W\u00f6lfl-Duchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sanz-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vychytil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stimpfl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/089686080502500311","article-title":"Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis","volume":"25","author":"P\u00e9rez Fontan","year":"2005","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.cmi.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1038\/s41598-018-22335-4","article-title":"Association between causes of peritoneal dialysis technique failure and all-cause mortality","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ackd.2018.09.002","article-title":"Peritoneal dialysis access associated infections","volume":"26","author":"Bieber","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.cmi.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/08968608221080586","article-title":"ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment","volume":"42","author":"Li","year":"2022","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.cmi.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/0886022X.2021.1939050","article-title":"Peritoneal dialysis-related peritonitis caused by Gram-negative organisms: ten-years experience in a single center","volume":"43","author":"Zeng","year":"2021","journal-title":"Ren Fail"},{"key":"10.1016\/j.cmi.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2215\/CJN.00630117","article-title":"Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes","volume":"12","author":"Whitty","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"NONMEM tutorial part I: description of commands and options, with simple examples of population analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.cmi.2023.06.002_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02446-17","article-title":"Avibactam pharmacokinetic\/pharmacodynamic targets","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jcph.793","article-title":"Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment","volume":"57","author":"Merdjan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1002\/phar.1840","article-title":"Pharmacokinetics of ceftazidime-avibactam in two patients with KPC-producing Klebsiella pneumoniae bacteremia and renal impairment","volume":"36","author":"Veillette","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2023.06.002_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00464-17","article-title":"Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/49.1.121","article-title":"Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections","volume":"49","author":"Buijk","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0896860819893820","article-title":"Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis","volume":"40","author":"Triyawatanyu","year":"2020","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.cmi.2023.06.002_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/8.suppl_B.277","article-title":"The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers","volume":"8","author":"Wise","year":"1981","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/0003-4819-117-3-215","article-title":"The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites","volume":"117","author":"Runyon","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1128\/AAC.01586-06","article-title":"Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo","volume":"51","author":"Mouton","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/AAC.01463-13","article-title":"Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia","volume":"58","author":"MacVane","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-018-0705-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of ceftazidime-avibactam combination: a model-informed strategy for its clinical development","volume":"58","author":"Sy","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.00080-14","article-title":"Activities of ceftazidime and avibactam against beta-lactamase-producing\u00a0Enterobacteriaceae in a hollow-fiber pharmacodynamic model","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.01269-15","article-title":"Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection","volume":"60","author":"Berkhout","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.06.002_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157870","article-title":"Deciphering the contribution of biofilm to the pathogenesis of peritoneal\u00a0dialysis\u00a0infections: characterization and microbial behaviour on dialysis fluids","volume":"11","author":"Sampaio","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3747\/pdi.2010.00178","article-title":"Impact of various peritoneal dialysis solutions on the growth of common bacterial and yeast pathogens","volume":"31","author":"Tobudic","year":"2011","journal-title":"Perit Dial Int"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:35:54Z","timestamp":1761118554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2300277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1198743X2300277X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.06.002","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma and intraperitoneal pharmacokinetics of ceftazidime\/avibactam in peritoneal dialysis patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}